Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 3

Results For "Glenmark-Pharmaceuticals-Ltd"

39 News Found

Cosmo and Glenmark sign distribution and license agreements for Winlevi in Europe and South Africa
Supply Chain | September 28, 2023

Cosmo and Glenmark sign distribution and license agreements for Winlevi in Europe and South Africa

Glenmark will receive from Cassiopea, a subsidiary of Cosmo, the exclusive right to commercialize Winlevi in 15 EU countries


Glenmark Pharmaceuticals receives sANDA approval for Tacrolimus Ointment, 0.03%
Drug Approval | August 17, 2023

Glenmark Pharmaceuticals receives sANDA approval for Tacrolimus Ointment, 0.03%

Glenmark's current portfolio consists of 184 products authorized for distribution in the U.S. marketplace


Glenmark sets GHG emission targets for FY2035
Sustainability | June 01, 2023

Glenmark sets GHG emission targets for FY2035

The target boundary includes biogenic land?related emissions and removals from bioenergy feedstock


Glenmark receives ANDA approval for Prochlorperazine Maleate Tablets
Drug Approval | March 21, 2023

Glenmark receives ANDA approval for Prochlorperazine Maleate Tablets

According to IQVIA sales data for the 12-month period ending January 2023, the Compazine Tablets, 5 mg and 10 mg market achieved annual sales of approximately US $26.9 million


Glenmark Pharmaceuticals receives 2nd ANDA tentative approval for Saxagliptin Tablets, 2.5 mg and 5 mg
Drug Approval | February 18, 2023

Glenmark Pharmaceuticals receives 2nd ANDA tentative approval for Saxagliptin Tablets, 2.5 mg and 5 mg

According to IQVIA sales data for the 12-month period ending December 2022, the Onglyza Tablets, 2.5 mg and 5 mg market achieved annual sales of approximately US $122.3 million


Glenmark Pharma reports Q3 FY 2022-23 revenue growth of 9.2%; PAT growth of 21.3%
News | February 11, 2023

Glenmark Pharma reports Q3 FY 2022-23 revenue growth of 9.2%; PAT growth of 21.3%

Profit After Tax (PAT) for the quarter ended December 31, 2022 was at Rs. 290.8 crore as compared to Rs. 239.8 crore in the previous corresponding quarter, registering a growth of 21.3% YoY


Glenmark launches AKYNZEO I.V. in India
News | January 24, 2023

Glenmark launches AKYNZEO I.V. in India

It is administered as a single infusion 30 minutes prior to the start of each chemotherapy cycle that helps prevent, both, acute and delayed phases of CINV


Heart failure treatment becomes affordable with Glenmark launching Sacubitril + Valsartan tablets
News | January 18, 2023

Heart failure treatment becomes affordable with Glenmark launching Sacubitril + Valsartan tablets

Sacu V is priced at Rs. 19 per tablet for a dose of 50 mg (sacubitril 24 mg + valsartan 26 mg)


Glenmark to divest select dermatology brands for Rs. 340.48 Cr
News | January 18, 2023

Glenmark to divest select dermatology brands for Rs. 340.48 Cr

The divested brands include Onabet, Halovate, Sorvate, Luligee, Demelan, Aceret, Dosetil, Revize, and Powercort, and their sub-brands